183 related articles for article (PubMed ID: 10722164)
1. An investigation of antibody acyl hydrolysis catalysis using a large set of related haptens.
Odenbaugh AL; Helms ED; Iverson BL
Bioorg Med Chem; 2000 Feb; 8(2):413-26. PubMed ID: 10722164
[TBL] [Abstract][Full Text] [Related]
2. Evolution of catalytic antibody repertoire in autoimmune mice.
Nishi Y
J Immunol Methods; 2002 Nov; 269(1-2):213-33. PubMed ID: 12379363
[TBL] [Abstract][Full Text] [Related]
3. Efficient and selective p-nitrophenyl-ester-hydrolyzing antibodies elicited by a p-nitrobenzyl phosphonate hapten.
Tawfik DS; Lindner AB; Chap R; Eshhar Z; Green BS
Eur J Biochem; 1997 Mar; 244(2):619-26. PubMed ID: 9119032
[TBL] [Abstract][Full Text] [Related]
4. Polyclonal antibody catalytic variability.
Stephens DB; Thomas RE; Stanton JF; Iverson BL
Biochem J; 1998 May; 332 ( Pt 1)(Pt 1):127-34. PubMed ID: 9576860
[TBL] [Abstract][Full Text] [Related]
5. Evidence that the mechanism of antibody-catalysed hydrolysis of arylcarbamates can be determined by the structure of the immunogen used to elicit the catalytic antibody.
Boucher G; Said B; Ostler EL; Resmini M; Brocklehurst K; Gallacher G
Biochem J; 2007 Feb; 401(3):721-6. PubMed ID: 17020536
[TBL] [Abstract][Full Text] [Related]
6. Improvement in hydrolytic antibody activity by change in haptenic structure from phosphate to phosphonate with retention of a common leaving-group determinant: evidence for the 'flexibility' hypothesis.
Gul S; Sonkaria S; Pinitglang S; Florez-Alvarez J; Hussain S; Thomas EW; Ostler EL; Gallacher G; Resmini M; Brocklehurst K
Biochem J; 2003 Dec; 376(Pt 3):813-21. PubMed ID: 12946271
[TBL] [Abstract][Full Text] [Related]
7. Catalytic antibody activity elicited by active immunisation. Evidence for natural variation involving preferential stabilization of the transition state.
Gallacher G; Jackson CS; Searcey M; Goel R; Mellor GW; Smith CZ; Brocklehurst K
Eur J Biochem; 1993 May; 214(1):197-207. PubMed ID: 8508792
[TBL] [Abstract][Full Text] [Related]
8. A comparison of flexible and constrained haptens in eliciting antibody catalysts for paraoxon hydrolysis.
Spivak DA; Hoffman TZ; Moore AH; Taylor MJ; Janda KD
Bioorg Med Chem; 1999 Jun; 7(6):1145-50. PubMed ID: 10428386
[TBL] [Abstract][Full Text] [Related]
9. Analysis of hapten binding and catalytic determinants in a family of catalytic antibodies.
Ulrich HD; Schultz PG
J Mol Biol; 1998 Jan; 275(1):95-111. PubMed ID: 9451442
[TBL] [Abstract][Full Text] [Related]
10. Structural convergence in the active sites of a family of catalytic antibodies.
Charbonnier JB; Golinelli-Pimpaneau B; Gigant B; Tawfik DS; Chap R; Schindler DG; Kim SH; Green BS; Eshhar Z; Knossow M
Science; 1997 Feb; 275(5303):1140-2. PubMed ID: 9027317
[TBL] [Abstract][Full Text] [Related]
11. Augmenting the efficacy of anti-cocaine catalytic antibodies through chimeric hapten design and combinatorial vaccination.
Wenthur CJ; Cai X; Ellis BA; Janda KD
Bioorg Med Chem Lett; 2017 Aug; 27(16):3666-3668. PubMed ID: 28709828
[TBL] [Abstract][Full Text] [Related]
12. Transition state docking: a probe for noncovalent catalysis in biological systems. Application to antibody-catalyzed ester hydrolysis.
Tantillo DJ; Houk KN
J Comput Chem; 2002 Jan; 23(1):84-95. PubMed ID: 11913392
[TBL] [Abstract][Full Text] [Related]
13. Cocaine catalytic antibodies: the primary importance of linker effects.
Matsushita M; Hoffman TZ; Ashley JA; Zhou B; Wirsching P; Janda KD
Bioorg Med Chem Lett; 2001 Jan; 11(2):87-90. PubMed ID: 11206477
[TBL] [Abstract][Full Text] [Related]
14. Hapten design for the generation of catalytic antibodies.
Thomas NR
Appl Biochem Biotechnol; 1994; 47(2-3):345-72. PubMed ID: 7944348
[TBL] [Abstract][Full Text] [Related]
15. Aspects of antibody-catalyzed primary amide hydrolysis.
Titmas RC; Angeles TS; Sugasawara R; Aman N; Darsley MJ; Blackburn G; Martin MT
Appl Biochem Biotechnol; 1994; 47(2-3):277-90; discussion 291-2. PubMed ID: 7944343
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of a catalytic antibody with a serine protease active site.
Zhou GW; Guo J; Huang W; Fletterick RJ; Scanlan TS
Science; 1994 Aug; 265(5175):1059-64. PubMed ID: 8066444
[TBL] [Abstract][Full Text] [Related]
17. Unexpectedly high occurrence of catalytic antibodies in MRL/lpr and SJL mice immunized with a transition-state analog: is there a linkage to autoimmunity?
Tawfik DS; Chap R; Green BS; Sela M; Eshhar Z
Proc Natl Acad Sci U S A; 1995 Mar; 92(6):2145-9. PubMed ID: 7892238
[TBL] [Abstract][Full Text] [Related]
18. A bait and switch hapten strategy generates catalytic antibodies for phosphodiester hydrolysis.
Wentworth P; Liu Y; Wentworth AD; Fan P; Foley MJ; Janda KD
Proc Natl Acad Sci U S A; 1998 May; 95(11):5971-5. PubMed ID: 9600901
[TBL] [Abstract][Full Text] [Related]
19. A structural basis for transition-state stabilization in antibody-catalyzed hydrolysis: crystal structures of an abzyme at 1. 8 A resolution.
Kristensen O; Vassylyev DG; Tanaka F; Morikawa K; Fujii I
J Mol Biol; 1998 Aug; 281(3):501-11. PubMed ID: 9698565
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of the complex of a catalytic antibody Fab fragment with a transition state analog: structural similarities in esterase-like catalytic antibodies.
Charbonnier JB; Carpenter E; Gigant B; Golinelli-Pimpaneau B; Eshhar Z; Green BS; Knossow M
Proc Natl Acad Sci U S A; 1995 Dec; 92(25):11721-5. PubMed ID: 8524836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
